Fulcrum Therapeutics

General Information


We are a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined diseases in areas of high unmet medical need, with an initial focus on rare diseases. We have developed a proprietary product engine that we employ to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat the known root cause of genetically defined diseases. We are using our product engine to identify targets that can be drugged by small molecules regardless of the particular underlying mechanism of gene mis-expression.

Employees: 62
Founded: 2015
Contact Information
Address 26 Landsdowne Street, Cambridge, MA 02139, US
Phone Number (617) 651-8851
Web Address http://www.fulcrumtx.com
View Prospectus: Fulcrum Therapeutics
Financial Information
Market Cap $373.4mil
Revenues $0 mil (last 12 months)
Net Income $-71.3 mil (last 12 months)
IPO Profile
Symbol FULC
Exchange NASDAQ
Shares (millions): 4.5
Price range $16.00 - $16.00
Est. $ Volume $72.0 mil
Manager / Joint Managers Morgan Stanley/ BofA Securities/ SVB Leerink
CO-Managers -
Expected To Trade: 7/18/2019
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change